Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP546 | DOI: 10.1530/endoabs.41.EP546

1Medical University of Graz, Graz, Austria; 2Joanneum Research Graz, Graz, Austria.


Introduction: Continuous glucose monitoring (CGM) has become an essential tool in diabetes management. In order to use CGM for treatment decisions, CGM systems have to be reliable over a wide range of glycemia as well as in situations with rapidly changing glucose levels such as exercise or in the postprandial state.

Design: In this monocentric study we evaluated the performance of three commercially available CGM systems (Abbott Libre, Dexcom G4 Platinum, Medtronic Enlite) in 12 type 1 diabetic subjects (age 33±11 years, 42% women, BMI 22.5±2.4 kg/m2, diabetes duration 17±12 years, HbA1c 7.6±1.1%) over a period of 12 h. Routine clinical conditions were mimicked by meal and exercise tests. The sensors were inserted 24 h prior to the test in parallel and were calibrated according to manufacturers’ instructions. Reference plasma glucose samples were taken every 5 min throughout the study and measured with Super GL analyzer. Glucose measurement accuracy was assessed by mean absolute relative difference (MARD) for each CGM system overall, during exercise and postprandially.

Results: Overall MARD was 13.2±10.9% (Abbott), 16.8±12.3% (Dexcom) and 21.4±17.6% (Medtronic). During exercise (ex) and postprandially (pp) MARD was as follows: 8.7±5.9% (Abbott_ex), and 11.7±10.5% (Abbott_pp), 15.7±14.6% (Dexcom_ex) and 15.1±12.5% (Dexcom_pp), and 19.4±13.5% (Medtronic_ex) and 20.5±17.9% (Medtronic_pp), respectively.

Conclusion: Sensor performance was similar during the whole investigational period compared to exercise or the postprandial state. The Abbott sensor showed superior performance during all study phases. CGM might become an important tool to avoid exercise-related hypoglycemia which needs to be proven in large-scale studies.

Article tools

My recent searches

No recent searches.